KAHR Bio

 https://kahrbio.com/

Background

KAHR Bio is an Israeli clinical-stage biotechnology company founded in 2005, specializing in the development of innovative immunotherapeutics for cancer. Their lead drug, DSP107, is a first-in-class CD47x4-1BB bi-specific fusion protein designed to activate both the innate and adaptive immune systems specifically at the tumor site. The company is primarily focused on treating large indications with unmet needs, such as Microsatellite Stable Colorectal Cancer (MSS CRC) and Non-Small Cell Lung Cancer (NSCLC).